Physician profile
James M Mcghee
NPI 1003910019
$345.63
in general payments reported to CMS, 2019-2025
11 companies · $56.72 in 2025
The $56.72 reported for 2025 was less than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $115 · 2020: $32.32 · 2021: $14.16 · 2022: $101 · 2024: $26.81 · 2025: $56.72.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $83.53.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $83.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $152.24 | 2020-2025 | Bexsero, Pediarix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.04 | 2019-2020 | |
| Aimmune Therapeutics, INC. | $26.81 | 2024 | |
| Ironshore Pharmaceuticals INC. | $19.40 | 2019 | |
| Supernus Pharmaceuticals, INC. | $19.38 | 2025 | Qelbree |
| Verrica Pharmaceuticals INC. | $18.92 | 2025 | Ycanth |
| Pfizer INC. | $16.83 | 2019 | |
| Boston Scientific Corporation | $12.48 | 2019 | |
| Lilly USA, LLC | $11.54 | 2019 | |
| Amgen INC. | $11.02 | 2019 | |
| Shire North American Group INC | $10.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Mcghee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.